Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

APO611 > Drug Design > Flashcards

Drug Design Flashcards

1
Q

4 classifications of drugs

A
  1. Psychopharmaceutical agents acting on CNS
  2. Pharmacodynamic agents
  3. Chemotherapeutic agents
  4. Metabolic agents (eg, treatment of diabetes)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what are primary effects?

A

desired therapeutic effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what are secondary effects?

A

side effects, e.g. drowsiness, loss of appetite

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

define an agonist

A

a drug/substance that binds to a receptor and initiates the same action as the substance that normally binds to the receptor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

define an antagonist

A

a drug/substance that binds to a receptor and blocks or suppresses a normal biological response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

why do we need new drugs?

A
  • less side effects
  • prevent drug resistance and tolerance
  • improve treatment of a new disease
  • treat new diseases
  • to give specific action on new targets for treating a disease
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

9 stages of drug development

A
  1. Extraction of lead compound (usually a natural product)
  2. Check for activity
  3. Determine molecular structure
  4. Synthesize new related compounds with similar structures to determine responsible molecular features
  5. Check new compounds for activity
  6. Deduce molecular features responsible for activity
  7. Synthesize new compounds to optimise activity
  8. Test new compounds
  9. Select suitable compounds for development
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what is meant by pharmacokinetics?

A

it refers to the study of how a drug is absorbed, distributed, metabolized and eliminated by the body (ADME).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

advantages of small molecules when compared to macromolecules

A

Small molecules diffuse easily, easy to synthesize, cheap (£1 a day)

90% of therapeutics in pharmaceutical market are small molecules

Rapid diffusion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

aims in drug design (7)

A
  1. The drug should have a good selectivity for its target
  2. The drug should have a good level of activity for its target
  3. The drug should have minimum side effects
  4. The drug should be easily synthesized
  5. The drug should be chemically stable
  6. The drug should have acceptable pharmacokinetics properties
  7. The drug should be non-toxic
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

give an example of a drug that is neither specific or selective

A

antihistamines have many targets and many effects, e.g. drowsiness and dry eyes, etc.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

define a lead structure

A

“in medicine, a chemical compound that shows promise as a treatment for a disease and may lead to the development of a new drug. This molecule may letter be optimised to produce the final drug.”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what is a the goal of structural optimisation in drug development?

A
  • to increase efficacy of potency
  • to reduce toxicity and side effects - LD50
  • gjfghfjkagfbk
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

2 approaches to drug discovery

A

ligand based and target based

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

define ligand based drug design

A

ligand based drug design is lead by finding a molecule that expresses the wanted pharmacological effect without knowing its target.
- structure of ligand is known, target structure is unknown

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

define target based drug design

A
  • AKA rational or direct or structure-based drug design
  • involves identifying a specific target, such as a receptors or enzyme that is involved in a disease process
15
Q

what are the important considerations for preclinical trials?

A

Not teratogenic (causing birth defect)

Carcinogenic

LD50

Optimal route of administration

16
Q

how do we carry out preclinical testing of compounds?

A

in vitro (cell-based) and in vivo (animal-based) models

17
Q

what is preclinical testing?

A

an essential step in the drug development process that involves evaluating the safety, efficacy, and pharmacokinetic properties of potential drug candidates before they can proceed to clinical trials in humans.

18
Q

what is in vivo testing?

A

involves evaluating the compound’s effects in living organisms (animals) to provide a more comprehensive understanding of its pharmacokinetics, efficacy, safety, potential toxicities

19
Q

what is in vitro testing?

A

involves the studying the effects of the compound on isolated cells or cellular components in a controlled laboratory setting

20
Q

aim of lead optimisation

A

aims to maximize the interactions of a drug with its target binding site in order to improve activity, selectivity and to minimise side effects

21
Q

what are the principle phases of drug action?

A

Pharmaceutical phase - determines amount of drug available for absorption

Pharmacokinetic phase - determines amount of drug available for action

Pharmacodynamic phase - determines induction of therapeutic effect

22
Q

define potency

A
  • refers to the concentration or dose of a drug required to produce a specific effect
  • measured as EC50 or IC50
  • represents the drug’s strength or activity at a given receptor or target
23
Q

define efficacy

A
  • refers to the maximum response that a drug can produce regardless of dose or concentration
  • represents the drug’s ability to elicit a therapeutic effect or desired outcome
24
Q

define IC50

A

inhibitory concentration 50% - the concentration of a drug needed to inhibit a specific biological process target by 50%

25
Q

define GI50

A

(Growth Inhibition Concentration 50%):
GI50 is a measure of the concentration of a drug or compound required to inhibit the growth of cells, typically in cell-based assays or in cancer research.

26
Q

define LD50

A

(Lethal Dose 50%):
LD50 refers to the dose or concentration of a drug or compound that is lethal and causes death in 50% of the individuals or experimental subjects tested.
It is a measure of acute toxicity and is typically determined in preclinical studies using animal models.

27
Q

Factors influencing how drug reaches target?

A
  1. Hydrophilic/hydrophobic character
  2. Ionisation
  3. Size
  4. Chemical and metabolic stability
28
Q

why does hydrophobicity/hydrophilicity matter?

A

Drug must be hydrophobic enough to pass membrane, but not too much as it will sit in membrane and is toxic.
If drug is too hydrophilic then it cannot move through membrane at all.

APO611 (5 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions